Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial

Table 3 Body weight and risk factors for metabolic disease changes during the 12-week study

	Control(n = 79)		ADF(n = 90)		TRF(n = 95)		P-value
	Week 4	Week 12	Week 4	Week 12	Week 4	Week 12	Week 4	Week 12
Body weight (kg)	70.32 ± 6.75	71.77 ± 6.90	70.76 ± 7.76	71.28 ± 7.02	71.31 ± 7.04	71.67 ± 7.37	0.648	0.709
BMI	26.48 ± 1.60	26.64 ± 1.66	25.97 ± 1.75	26.15 ± 1.58	26.48 ± 1.38	26.60 ± 1.46	0.049	0.071
Fat mass (kg)	27.91 ± 3.53	28.01 ± 3.49	27.09 ± 2.52	27.10 ± 2.52	27.36 ± 3.44	27.65 ± 3.34	0.241	0.165
Lean mass (kg)	42.41 ± 7.28	42.71 ± 7.67	43.67 ± 7.61	44.17 ± 7.79	43.96 ± 7.18	44.04 ± 7.47	0.352	0.395
Waist circumference	88.29 ± 4.73	88.54 ± 5.10	88.99 ± 5.20	87.19 ± 4.88	89.70 ± 7.42	87.58 ± 4.39	0.590	0.174
Cholesterol (mg/dL)	4.45 ± 1.36	4.65 ± 1.36	3.95 ± 1.08	4.15 ± 1.06	4.03 ± 1.55	4.37 ± 1.53	0.039	0.055
Total Direct HDL(mg/dL)	1.29 ± 0.55	1.18 ± 0.51	1.28 ± 0.41	1.17 ± 0.38	1.18 ± 0.47	1.15 ± 0.45	0.206	0.920
LDL (mg/dL)	2.55 ± 0.79	2.51 ± 0.76	2.82 ± 0.85	2.79 ± 0.83	2.73 ± 0.88	2.71 ± 0.87	0.101	0.085
Triglycerides (mg/dL)	2.28 ± 1.70	2.40 ± 1.70	2.21 ± 1.91	2.12 ± 1.90	2.27 ± 1.75	2.31 ± 1.75	0.965	0.582
Glucose (mg/dL)	5.18 ± 0.072	4.94 ± 1.22	5.36 ± 1.32	5.19 ± 0.67	5.21 ± 1.06	5.05 ± 1.35	0.500	0.355
Liver stiffness (kpa)	18.39 ± 4.64	18.36 ± 3.84	18.03 ± 2.25	18.05 ± 2.84	18.13 ± 4.11	18.37 ± 3.65	0.825	0.766

ISSN: 1471-230X